Find Givinostat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 497833-27-9, Itf2357, Givinostat [inn], Givinostat free base, Itf-2357, [6-(diethylaminomethyl)naphthalen-2-yl]methyl n-[4-(hydroxycarbamoyl)phenyl]carbamate
Molecular Formula
C24H27N3O4
Molecular Weight
421.5  g/mol
InChI Key
YALNUENQHAQXEA-UHFFFAOYSA-N
FDA UNII
5P60F84FBH

Givinostat
Givinostat is an orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. Givinostat inhibits class I and class II HDACs, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. At low, nonapoptotic concentrations, this agent inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), IL-6 and interferon-gamma. Givinostat has also been shown to activate the intrinsic apoptotic pathway, inducing apoptosis in hepatoma cells and leukemic cells. This agent may also exhibit anti-angiogenic activity, inhibiting the production of angiogenic factors such as IL-6 and vascular endothelial cell growth factor (VEGF) by bone marrow stromal cells.
1 2D Structure

Givinostat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
2.1.2 InChI
InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
2.1.3 InChI Key
YALNUENQHAQXEA-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO
2.2 Other Identifiers
2.2.1 UNII
5P60F84FBH
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 497833-27-9

2. Itf2357

3. Givinostat [inn]

4. Givinostat Free Base

5. Itf-2357

6. [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate

7. 5p60f84fbh

8. Chembl1213492

9. 497833-27-9 (free Base)

10. (6-((diethylamino)methyl)naphthalen-2-yl)methyl (4-(hydroxycarbamoyl)phenyl)carbamate

11. (6-((diethylamino)methyl)naphthalen-2-yl)methyl(4-(hydroxycarbamoyl)phenyl)carbamate

12. [4-[(hydroxyamino)carbonyl]phenyl]carbamic Acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl Ester

13. Gavinostat

14. 4-[(hydroxyamino)carbonyl]phenyl]carbamic Acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl Ester

15. Unii-5p60f84fbh

16. {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate

17. Gavinostat;itf-2357

18. Gtpl7490

19. Schembl1555814

20. Chebi:94187

21. Dtxsid70198049

22. Bcp29856

23. Zinc3820616

24. Bdbm50105329

25. Cs-4727

26. Db12645

27. Ex-5958

28. [6-(diethylaminomethyl)-2-naphthyl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate

29. Ac-31380

30. Bcb04_000011

31. Hy-14842

32. Ec-000.2471

33. 833h279

34. A923985

35. Q426257

36. Gavinostat; Itf-2357; Itf2357; Itf 2357

37. Brd-k13810148-001-01-3

38. Carbamic Acid, (4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl Ester

39. Qcm

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 421.5 g/mol
Molecular Formula C24H27N3O4
XLogP33.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count9
Exact Mass421.20015635 g/mol
Monoisotopic Mass421.20015635 g/mol
Topological Polar Surface Area90.9 Ų
Heavy Atom Count31
Formal Charge0
Complexity575
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Juvenile idiopathic arthritis


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty